Q1 2025 Earnings Summary
- Strong Immunology Performance: AbbVie’s core immunology assets, Skyrizi and Rinvoq, delivered robust demand leading to upward revisions in guidance (Skyrizi increased by approximately $600 million to $16.5 billion and Rinvoq by $300 million), demonstrating solid market momentum and strong fundamentals.
- Robust Manufacturing & Capital Investment: The company’s extensive U.S. manufacturing network—spanning 11 sites with plans to add more capacity and over $10 billion of capital investment planned over the next decade—ensures supply reliability and cost efficiencies, mitigating potential external disruptions.
- Promising Pipeline Innovation: Ongoing combination trials in immunology, expected to yield early data next year, along with advancing novel treatments in oncology, neuroscience, and obesity, position AbbVie for long-term growth through multiple therapeutic avenues and enhanced market differentiation.
- Humira's Ongoing Erosion: The continued volume decline and nearly 49.5% operational drop in global Humira sales—accelerated by biosimilar competition—could significantly drag on future overall revenue and margins.
- Pricing Headwinds for Key Immunology Assets: Despite strong demand in the quarter, both Skyrizi and Rinvoq face anticipated negative pricing headwinds over the full year, which may pressure margins and dilute overall profitability.
- Uncertainty from Trade Policy and Tariffs: Potential shifts in U.S. trade policies and the looming risk of pharmaceutical sector tariffs introduce uncertainty. Even though the current estimated impact on aesthetics is modest (~$30 million), further policy changes could exacerbate cost pressures and disrupt supply chains.
| Metric | YoY Change | Reason |
|---|---|---|
Acquired IPR&D and Milestones (FY2024) | Increased from $778 million in FY2023 to $2.757 billion in FY2024 | The large increase was primarily driven by significant upfront acquisition payments: AbbVie paid $1.4 billion for Aliada Therapeutics and $250 million for Celsius Therapeutics, which far outweighed the change in development milestone payments (declining from $196 million in FY2023 to $130 million in FY2024). |
Acquired IPR&D and Milestones (Q1 2025) | Increased from $164 million in Q1 2024 to $248 million in Q1 2025 (+51% YoY) | The Q1 2025 increase reflects impending uncertainties in future asset acquisitions and licensing agreements: Although specific transactions beyond the first quarter were not detailed, the guidance indicates that similar transaction-driven expenses, driven by executed collaborations or licensing deals, are contributing to the expense rise, despite the inherent uncertainty in timing. |
| Metric | Period | Previous Guidance | Current Guidance | Change |
|---|---|---|---|---|
Adjusted EPS | FY 2025 | $12.12 to $12.32 | $12.09 to $12.29 | lowered |
Total Net Revenues | FY 2025 | Approximately $59 billion | $59.7 billion | raised |
Adjusted Gross Margin | FY 2025 | 84% of sales | 84% of sales | no change |
Adjusted SG&A Expense | FY 2025 | Approximately $13.2 billion | $13.2 billion | no change |
Adjusted Operating Margin Ratio | FY 2025 | 47% of sales | 46.5% of sales | lowered |
Net Revenues | Q1 2025 | Approximately $12.8 billion | no current guidance | no current guidance |
Adjusted EPS | Q1 2025 | $2.47 to $2.51 | no current guidance | no current guidance |
Operating Margin Ratio | Q1 2025 | 44.5% | no current guidance | no current guidance |
Foreign Exchange Impact | Q1 2025 | 1.6% unfavorable impact | no current guidance | no current guidance |
Net Revenues | Q2 2025 | no prior guidance | $15 billion | no prior guidance |
Adjusted EPS | Q2 2025 | no prior guidance | $3.26 to $3.30 | no prior guidance |
Operating Margin Ratio | Q2 2025 | no prior guidance | 49.5% | no prior guidance |
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Immunology Performance | Consistently characterized by robust growth of Skyrizi and Rinvoq with detailed discussions on volume‐driven gains and modest low‐single digit price concessions in Q2–Q4 2024 ( , , ) | Q1 2025 continues to emphasize strong demand with over 65% combined growth, while noting slightly negative full‑year pricing headwinds ( , , ) | Consistent robust growth with persistent, manageable pricing headwinds. |
Humira Erosion due to Biosimilar Competition | All earlier quarters (Q2–Q4 2024) detailed significant sales declines, volume compression, and evolving rebates due to biosimilar competition ( , , ) | Q1 2025 reports faster share erosion and volume declines; the narrative stresses that erosion remains a key headwind going into the year ( , , ) | Ongoing market share loss, with an accelerated decline noted in Q1 2025. |
Aesthetics Business Outlook | Earlier calls (Q2–Q4 2024) discussed near‐term economic headwinds, market share challenges in toxins and fillers, and long‑term growth potential driven by innovation ( , , , ) | Q1 2025 maintains that economic headwinds persist but highlights innovation (e.g. BoNT/E) and a cautious yet optimistic long‑term view ( , ) | Recurring near‑term challenges yet maintained optimism for long‑term growth. |
Pipeline Innovation and Diversification | Q2–Q4 2024 emphasized a robust, diversified pipeline across oncology, neuroscience, and immunology with growing deal activity; obesity was mentioned but less prominently ( , , ) | Q1 2025 expands the focus to include a stronger emphasis on obesity alongside oncology, neuroscience, and immunology with new data and strategic asset advancement ( , , ) | Broader diversification with enhanced emphasis on obesity and deeper pipeline developments. |
Manufacturing and Capital Investment Strategy | Not mentioned in Q2–Q4 2024 earnings discussions | Q1 2025 introduces detailed plans for expanding the U.S. manufacturing footprint with 4 new plants and over $10 billion in capital investment, also addressing anti‑tariff strategies ( , , ) | A new strategic focus on U.S. manufacturing expansion and tariff mitigation. |
Strategic M&A and Business Development Activities | Q2–Q4 2024 consistently highlighted a strong track record of acquisitions (e.g. Allergan, Cerevel) and early‑stage deals to bolster pipeline depth ( , , ) | Q1 2025 underscores further acquisitions (e.g. Nimble Therapeutics) and licenses (with Gubra) to drive growth in immunology, neuroscience, and obesity ( , , ) | Steady M&A momentum with new deals targeting growth areas and pipeline expansion. |
Trade Policy and Tariff Uncertainty | No mention in previous periods | Q1 2025 discusses potential pharmaceutical tariffs, their modest impacts (e.g. ~$30 million on aesthetics), and mitigation strategies leveraging U.S. manufacturing expansion ( , , ) | An emerging topic in Q1 2025, reflecting rising concerns about trade policy impacts. |
Medicare Part D Redesign Impact | Q2 and Q4 2024 provided specific figures with a 3–4% headwind and multi‑billion-dollar adverse effect on revenue, particularly affecting key products ( , , , ) | Q1 2025 references the redesign in terms of transparency and impact assessment without detailed quantification, indicating a shift in communication style ( ) | A consistent challenge, though Q1 2025 is less specific as the company adopts a “full understanding then transparent” approach. |
Emerging Oncology Asset (Tmab-A/ABBV-400) Potential | Q2–Q4 2024 detailed encouraging Phase I data, planned Phase II/III studies, and potential uses across NSCLC, CRC, and gastroesophageal cancers ( , , ) | Q1 2025 continues the asset’s development with updated plans for combination studies and upcoming data presentations at ASCO, reinforcing its multi-indication potential ( ) | Steady advancement with expanding clinical programs and reinforcing its potential across multiple cancer types. |
Neuroscience Portfolio Uncertainty (Cerevel Acquisition) | Q2 revealed progress toward completing the Cerevel deal; Q3 mentioned uncertainties (placebo effects, pivotal study challenges) and Q4 discussed intangible asset impairments alongside cautious optimism ( , , ) | Q1 2025 shifts focus to positive pipeline elements like Tavapadon with optimistic regulatory prospects, with less emphasis on uncertainties compared to previous calls ( , , ) | A reduction in expressed uncertainty, suggesting improved clarity or integration of Cerevel assets. |
Pricing Dynamics and Contracting Negotiations Impacting Revenue | Across Q2–Q4 2024, discussions centered on low single-digit price erosion, scheduled contracting renewals, and the interplay of rebates and volume growth ( , , , ) | Q1 2025 maintains the narrative of modest pricing concessions but also highlights better-than-expected revenue outcomes and improved EPS guidance driven by volume strength ( , , ) | A consistent trend of modest concessions offset by strong volume; Q1 2025 shows a slightly more favorable contracting outcome. |
-
Immunology Guidance
Q: Which indications drove raised guidance?
A: Management raised Skyrizi’s revenue forecast by $600M (split $200M psoriatic, $400M IBD) and Rinvoq’s by $300M (evenly across indications), boosting full-year EPS guidance to $12.09–$12.29. -
Immunology Pricing
Q: What’s the trend in immunology pricing?
A: Despite strong demand for Skyrizi and Rinvoq, minor negative pricing headwinds are expected for the full year, with favorable quarterly pricing partly due to effective co‐pay management. -
Government Policy
Q: How will U.S. policies impact the sector?
A: Management is closely engaging with lawmakers to balance affordability and innovation while mitigating risks from potential price controls and trade policy shifts. -
Aesthetics Tariffs
Q: How do tariffs affect the aesthetics business?
A: The modest tariff impact, estimated at about $30 million globally, has been absorbed in guidance with no major change in demand particularly in China. -
Tariff Mitigation & IP
Q: How are tariff risks and IP domiciling managed?
A: The company employs inventory tactics, alternative sourcing, and robust U.S. investments while maintaining a strong IP profile similar to its peers. -
Drug Pricing Regulations
Q: Could pricing controls hurt earnings?
A: AbbVie remains flexible and well-positioned to pivot to alternative strategies if new pricing regulations were imposed, protecting innovation and growth. -
Reciprocal Tariffs & Destocking
Q: Did destocking or tariffs impact quarterly pricing?
A: Limited retail destocking contributed modestly to pricing dynamics, with overall strong demand minimizing the impact from reciprocal tariffs. -
Advertising Restrictions
Q: Might advertising restrictions affect our edge?
A: AbbVie values First Amendment rights and is prepared to shift focus toward disease awareness if mass media restrictions were ever imposed. -
Inventory & BoNT/E Pricing
Q: Is U.S. inventory sufficient; pricing strategy for BoNT/E?
A: Current U.S. inventory levels adequately support key products, while the pricing strategy for BoNT/E will be finalized during the launch process. -
PBM Reform & BD Focus
Q: What are priorities in PBM reform and BD?
A: The focus remains on patient affordability with ongoing business development in immunology and expanding neuroscience pipelines. -
Manufacturing Footprint
Q: How is the U.S. versus OUS manufacturing balanced?
A: AbbVie continues investing in a robust U.S. manufacturing network while maintaining strategic international capabilities to ensure supply security. -
Combination Trials
Q: When will combination study data emerge?
A: Skyrizi/Rinvoq combination trials have started, with early data expected next year and multiple combination mechanisms under exploration. -
Obesity Dosing Strategy
Q: What is the dosing plan for the obesity asset?
A: Early studies with the long-acting amylin analog showed promising weight loss at 2 mg; higher doses and extended intervals are under evaluation for stronger efficacy. -
Schizophrenia Asset Outlook
Q: What is the future of the schizophrenia asset?
A: AbbVie sees potential for the schizophrenia asset by further exploring higher dosing in a stepwise study design to derive clearer efficacy signals.